MicroRNA‑425 upregulation indicates better prognosis in younger acute myeloid leukemia patients undergoing chemotherapy

  • Authors:
    • Jilei Zhang
    • Jinlong Shi
    • Gaoqi Zhang
    • Xinpei Zhang
    • Xinrui Yang
    • Siyuan Yang
    • Jing Wang
    • Kai Hu
    • Xiaoyan Ke
    • Lin Fu
  • View Affiliations

  • Published online on: April 4, 2019     https://doi.org/10.3892/ol.2019.10217
  • Pages: 5793-5802
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to investigate whether the expression levels of microRNA‑425 (miR‑425) were associated with the prognosis of acute myeloid leukemia (AML) in patients treated with chemotherapy or allogeneic hematopoietic stem cell transplantation (allo‑HSCT). A total of 162 AML patients were enrolled and divided into chemotherapy and allo‑HSCT groups. Next, the overall survival (OS) and event‑free survival (EFS) were compared between patients with high and low miR‑425 expression in each of the treatment groups. In the chemotherapy group, high miR‑425 expression was favorable for EFS (P=0.001) and OS (P=0.001) in younger patients (<60 years), whereas it had no effect on EFS and OS in older patients (≥60 years). In the allo‑HSCT group, there was no association between miR‑425 expression levels and clinical outcomes. Further analyses suggested that in the low miR‑425 expression group, EFS and OS were longer in patients treated with allo‑HSCT as compared with those treated with chemotherapy (both P<0.001), whereas no significant differences were observed in the high miR‑425 expression group. In conclusion, the current data indicated that miR‑425 is an independent favorable prognostic factor for younger AML patients undergoing chemotherapy, and its use may facilitate clinical decision‑making in selecting treatment for AML patients. Patients with low miR‑425 expression may benefit from allo‑HSCT, whereas allo‑HSCT did not appear to be beneficial in patients with high miR‑425 expression.

References

1 

Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, et al: Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 374:2209–2221. 2016. View Article : Google Scholar : PubMed/NCBI

2 

Tsai CH, Hou HA, Tang JL, Liu CY, Lin CC, Chou WC, Tseng MH, Chiang YC, Kuo YY, Liu MC, et al: Genetic alterations and their clinical implications in older patients with acute myeloid leukemia. Leukemia. 30:1485–1492. 2016. View Article : Google Scholar : PubMed/NCBI

3 

Ustun C and Marcucci G: Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia. Curr Opin Hematol. 22:85–91. 2015. View Article : Google Scholar : PubMed/NCBI

4 

Dohner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, et al: Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the european leukemianet. Blood. 115:453–474. 2010. View Article : Google Scholar : PubMed/NCBI

5 

Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, et al: Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 129:424–447. 2017. View Article : Google Scholar : PubMed/NCBI

6 

Brunetti L, Gundry MC and Goodell MA: DNMT3A in Leukemia. Cold Spring Harb Perspect Med. 7:a0303202017. View Article : Google Scholar : PubMed/NCBI

7 

Meyer SC and Levine RL: Translational implications of somatic genomics in acute myeloid leukaemia. Lancet Oncol. 15:e382–e394. 2014. View Article : Google Scholar : PubMed/NCBI

8 

Metzeler KH, Herold T, Rothenberg-Thurley M, Amler S, Sauerland MC, Görlich D, Schneider S, Konstandin NP, Dufour A, Bräundl K, et al: Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 128:686–698. 2016. View Article : Google Scholar : PubMed/NCBI

9 

Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, et al: Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 366:1079–1089. 2012. View Article : Google Scholar : PubMed/NCBI

10 

Marcucci G, Mrozek K, Radmacher MD, Garzon R and Bloomfield CD: The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood. 117:1121–1129. 2011. View Article : Google Scholar : PubMed/NCBI

11 

Zhou X, Wen W, Shan X, Zhu W, Xu J, Guo R, Cheng W, Wang F, Qi LW, Chen Y, et al: A six-microRNA panel in plasma was identified as a potential biomarker for lung adenocarcinoma diagnosis. Oncotarget. 8:6513–6525. 2017.PubMed/NCBI

12 

Garzon R, Marcucci G and Croce CM: Targeting microRNAs in cancer: Rationale, strategies and challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI

13 

Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F, Fabbri M, Coombes K, Alder H, Nakamura T, et al: MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 111:3183–3189. 2008. View Article : Google Scholar : PubMed/NCBI

14 

Schwind S, Maharry K, Radmacher MD, Mrózek K, Holland KB, Margeson D, Whitman SP, Hickey C, Becker H, Metzeler KH, et al: Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study. J Clin Oncol. 28:5257–5264. 2010. View Article : Google Scholar : PubMed/NCBI

15 

Sun SM, Rockova V, Bullinger L, Dijkstra MK, Döhner H, Löwenberg B and Jongen-Lavrencic M: The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML. Leukemia. 27:100–106. 2013. View Article : Google Scholar : PubMed/NCBI

16 

Zhang Z, Wen M, Guo J, Shi J, Wang Z, Tan B, Zhang G, Zheng X and Zhang A: Clinical value of miR-425-5p detection and its association with cell proliferation and apoptosis of gastric cancer. Pathol Res Pract. 213:929–937. 2017. View Article : Google Scholar : PubMed/NCBI

17 

Fang F, Song T, Zhang T, Cui Y, Zhang G and Xiong Q: MiR-425-5p promotes invasion and metastasis of hepatocellular carcinoma cells through SCAI-mediated dysregulation of multiple signaling pathways. Oncotarget. 8:31745–31757. 2017.PubMed/NCBI

18 

Zhang Y, Hu X, Miao X, Zhu K, Cui S, Meng Q, Sun J and Wang T: MicroRNA-425-5p regulates chemoresistance in colorectal cancer cells via regulation of programmed cell death 10. J Cell Mol Med. 20:360–369. 2016. View Article : Google Scholar : PubMed/NCBI

19 

Sun L, Jiang R, Li J, Wang B, Ma C, Lv Y and Mu N: MicoRNA-425-5p is a potential prognostic biomarker for cervical cancer. Ann Clin Biochem. 54:127–133. 2017. View Article : Google Scholar : PubMed/NCBI

20 

Yan YF, Gong FM, Wang BS and Zheng W: MiR-425-5p promotes tumor progression via modulation of CYLD in gastric cancer. Eur Rev Med Pharmacol Sci. 21:2130–2136. 2017.PubMed/NCBI

21 

Liu P, Hu Y, Ma L, Du M, Xia L and Hu Z: miR-425 inhibits melanoma metastasis through repression of PI3K-Akt pathway by targeting IGF-1. Biomed Pharmacother. 75:51–57. 2015. View Article : Google Scholar : PubMed/NCBI

22 

Cancer Genome Atlas Research Network, . Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 368:2059–2074. 2013. View Article : Google Scholar : PubMed/NCBI

23 

Conway O'Brien E, Prideaux S and Chevassut T: The epigenetic landscape of acute myeloid leukemia. Adv Hematol. 2014:1031752014.PubMed/NCBI

24 

Marcucci G, Metzeler KH, Schwind S, Becker H, Maharry K, Mrózek K, Radmacher MD, Kohlschmidt J, Nicolet D, Whitman SP, et al: Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol. 30:742–750. 2012. View Article : Google Scholar : PubMed/NCBI

25 

Gupta V, Tallman MS and Weisdorf DJ: Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: Myths, controversies, and unknowns. Blood. 117:2307–2318. 2011. View Article : Google Scholar : PubMed/NCBI

26 

Schmid C, Labopin M, Socie G, Daguindau E, Volin L, Huynh A, Bourhis JH, Milpied N, Cornelissen J, Chevallier P, et al: Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. Blood. 126:2062–2069. 2015. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Zhang, J., Shi, J., Zhang, G., Zhang, X., Yang, X., Yang, S. ... Fu, L. (2019). MicroRNA‑425 upregulation indicates better prognosis in younger acute myeloid leukemia patients undergoing chemotherapy. Oncology Letters, 17, 5793-5802. https://doi.org/10.3892/ol.2019.10217
MLA
Zhang, J., Shi, J., Zhang, G., Zhang, X., Yang, X., Yang, S., Wang, J., Hu, K., Ke, X., Fu, L."MicroRNA‑425 upregulation indicates better prognosis in younger acute myeloid leukemia patients undergoing chemotherapy". Oncology Letters 17.6 (2019): 5793-5802.
Chicago
Zhang, J., Shi, J., Zhang, G., Zhang, X., Yang, X., Yang, S., Wang, J., Hu, K., Ke, X., Fu, L."MicroRNA‑425 upregulation indicates better prognosis in younger acute myeloid leukemia patients undergoing chemotherapy". Oncology Letters 17, no. 6 (2019): 5793-5802. https://doi.org/10.3892/ol.2019.10217